Progressive Supranuclear Palsy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Progressive Supranuclear Palsy – Drugs In Development, 2024 report and make more profitable business decisions.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome, is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech, and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, and behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.
The Progressive Supranuclear Palsy drugs in development market research report provide comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Progressive Supranuclear Palsy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 37 molecules, with 35 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Progressive Supranuclear Palsy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Progressive Supranuclear Palsy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Progressive Supranuclear Palsy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allyx Therapeutics IncAlterity Therapeutics Ltd
AlzProtect SAS
Amylyx Pharmaceuticals Inc
Anhorn Medicines Co Ltd
Aprinoia Therapeutics Inc
Arvinas Inc
Asceneuron SA
Autotac Bio Inc
AZTherapies Inc
Biogen Inc
Bristol-Myers Squibb Co
Cortice Biosciences Inc
GemVax & KAEL Co Ltd
Grupo Ferrer Internacional SA
Korea Institute of Science and Technology
Neural Stem Cell Institute
NeuroTau Inc
New Amsterdam Sciences Inc
Novartis AG
Oligomerix inc
Pinteon Therapeutics Inc
ProMIS Neurosciences Inc
reMYND NV
Retrotope Inc
TauC3 Biologics Ltd
TauRx Therapeutics Ltd
Transposon Therapeutics Inc
UCB SA
Vaxxinity Inc
Velacor Therapeutics Pty Ltd (Inactive)
Voyager Therapeutics Inc
Woolsey Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Progressive Supranuclear Palsy reports